InsiderPulseNo transactions found.
| Metric | FY2021 |
|---|---|
| Professional fees and other expenses | $3.7M |
| Franchise tax expense | $164K |
| Loss from operations | -$3.9M |
| Interest and dividend income on investments held in Trust Account | $9K |
| Net Loss | -$3.9M |
| Common Class A [Member] | |
| Basic and diluted weighted average shares outstanding | shares | $5.4M |
| Basic and diluted net loss per share | $ / shares | -$0.17 |
| Common Class B [Member] | |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Senti Biosciences GAAP EPS of -$0.14, revenue of $0.01M
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026